Skip to content

Company
Pipeline
For Investors
Contact

Company
Pipeline
For Investors
Contact

Press Releases

Choose Year
Search Press Releases

Found 269 Results

January 10, 2020

Relmada Therapeutics Strengthens Financial Operations with Addition of Maged Shenouda as Chief Financial Officer

December 20, 2019

Relmada Therapeutics Strengthens Board of Directors with Appointments of Life Sciences Industry Veterans, Eric Schmidt, Ph.D., and John Glasspool

December 9, 2019

Relmada Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

December 3, 2019

Relmada Therapeutics Announces Proposed Public Offering of Common Stock

December 3, 2019

Relmada Therapeutics Announces Pricing of Public Offering of Common Stock

October 17, 2019

Relmada to Ring NASDAQ Stock Market Opening Bell on Friday, October 18

October 15, 2019

Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression

October 14, 2019

Relmada Therapeutics to Announce Results of Phase 2 Study of REL-1017 for Treatment Resistant Depression and Conduct Conference Call on Tuesday, October 15

October 10, 2019

Relmada Therapeutics Announces Commencement of Trading on The NASDAQ Capital Market

October 8, 2019

Relmada Therapeutics Announces Uplisting to The NASDAQ Capital Market

«...13 141516 17 18...»

IR Contact

Brian Ritchie
LifeSci Advisors, LLC

+1 (212) 915-2578
britchie@lifesciadvisors.com

Email Alerts Sign-Up

Email

I accept the Privacy Policy^*

Unsubscribe

Loading...

Company

Pipeline
Overview
NDV-01
Speranolone

For Investors
Summary
News
Events
SEC Filings
Corporate Governance
Stock Information

Contact

info@relmada.com

+1 (786) 629-1376

©2026 Relmada Therapeutics, Inc.

Privacy Policy
Terms of Use

Scroll to Top